194 related articles for article (PubMed ID: 35651604)
21. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
[TBL] [Abstract][Full Text] [Related]
22. A Risk Score Model Based on Nine Differentially Methylated mRNAs for Predicting Prognosis of Patients with Clear Cell Renal Cell Carcinoma.
Zhou J; Liu G; Wu X; Zhou Z; Li J; Ji Z
Dis Markers; 2021; 2021():8863799. PubMed ID: 33510822
[TBL] [Abstract][Full Text] [Related]
23. Identification of a four immune-related genes signature based on an immunogenomic landscape analysis of clear cell renal cell carcinoma.
Gao X; Yang J; Chen Y
J Cell Physiol; 2020 Dec; 235(12):9834-9850. PubMed ID: 32452055
[TBL] [Abstract][Full Text] [Related]
24. Construction of a ferroptosis-related signature based on seven lncRNAs for prognosis and immune landscape in clear cell renal cell carcinoma.
Wei SY; Feng B; Bi M; Guo HY; Ning SW; Cui R
BMC Med Genomics; 2022 Dec; 15(1):263. PubMed ID: 36528763
[TBL] [Abstract][Full Text] [Related]
25. Identification and validation of an immune-related gene prognostic signature for clear cell renal carcinoma.
Hua S; Xie Z; Zhang Y; Wu L; Shi F; Wang X; Xia S; Dong S; Jiang J
Front Immunol; 2022; 13():869297. PubMed ID: 35936012
[TBL] [Abstract][Full Text] [Related]
26. The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma.
Yuan H; Qin X; Wang J; Yang Q; Fan Y; Xu D
Front Immunol; 2022; 13():971142. PubMed ID: 36131921
[TBL] [Abstract][Full Text] [Related]
27. Identification of a three-miRNA signature as a novel potential prognostic biomarker in patients with clear cell renal cell carcinoma.
Luo Y; Chen L; Wang G; Xiao Y; Ju L; Wang X
J Cell Biochem; 2019 Aug; 120(8):13751-13764. PubMed ID: 30957284
[TBL] [Abstract][Full Text] [Related]
28. Subtype recognition and identification of a prognosis model characterized by antibody-dependent cell phagocytosis-related genes in breast cancer.
Wang L; Li M; Yang H; Dai F; Xie N; Li L; Zhu M; Ding R
Aging (Albany NY); 2024 Feb; 16(4):4014-4032. PubMed ID: 38393698
[TBL] [Abstract][Full Text] [Related]
29. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
30. Construction of A Novel Ferroptosis-related Prognostic Risk Signature for Survival Prediction in Clear Cell Renal Cell Carcinoma Patients.
Tang F; Zhang J; Zhu L; Lai Y; Li Z; Lu Z; Tang Z; Mai Y; Huang R; He Z
Urol J; 2022 May; 19(4):289-299. PubMed ID: 35598038
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of a novel lncRNA profile reveals potential prognostic biomarkers in clear cell renal cell carcinoma.
Liu T; Sui J; Zhang Y; Zhang XM; Wu WJ; Yang S; Xu SY; Hong WW; Peng H; Yin LH; Pu YP; Liang GY
Oncol Rep; 2018 Sep; 40(3):1503-1514. PubMed ID: 30015930
[TBL] [Abstract][Full Text] [Related]
32. Pyroptosis-Related Gene Signature Predicts the Prognosis of ccRCC Using TCGA and Single-Cell RNA Seq Database.
Gan Y; Zhang Z; Wang X; Li A; Fan Y; Zhang Q
J Healthc Eng; 2022; 2022():8224618. PubMed ID: 36349258
[TBL] [Abstract][Full Text] [Related]
33. HJURP is a prognostic biomarker for clear cell renal cell carcinoma and is linked to immune infiltration.
Zhang F; Yuan D; Song J; Chen W; Wang W; Zhu G; Hu B; Chen X; Zhu J
Int Immunopharmacol; 2021 Oct; 99():107899. PubMed ID: 34217993
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide screening and cohorts validation identifying novel lncRNAs as prognostic biomarkers for clear cell renal cell carcinoma.
Zhang C; Huang D; Liu A; Xu Y; Na R; Xu D
J Cell Biochem; 2020 Mar; 121(3):2559-2570. PubMed ID: 31646670
[TBL] [Abstract][Full Text] [Related]
35. Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics.
Zhang S; Xu X; Wang Y; Zhu Y; Wang J; Wang H; Guo J
Ann Clin Lab Sci; 2021 Sep; 51(5):597-608. PubMed ID: 34686501
[TBL] [Abstract][Full Text] [Related]
36. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
[TBL] [Abstract][Full Text] [Related]
37. Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues.
Yoo SH; Yun J; Keam B; Hong SP; Ock CY; Koh J; Kim S; Jeon YK; Jung KC; Kim M; Kim TM; Kim DW; Kim JI; Heo DS
Cancer Immunol Immunother; 2021 Jun; 70(6):1755-1769. PubMed ID: 33389015
[TBL] [Abstract][Full Text] [Related]
38. Fifteen hub genes associated with progression and prognosis of clear cell renal cell carcinoma identified by coexpression analysis.
Wang Y; Chen L; Wang G; Cheng S; Qian K; Liu X; Wu CL; Xiao Y; Wang X
J Cell Physiol; 2019 Jul; 234(7):10225-10237. PubMed ID: 30417363
[TBL] [Abstract][Full Text] [Related]
39. Integrative analysis of TRPV family to prognosis and immune infiltration in renal clear cell carcinoma.
Gong Z; Xie J; Chen L; Tang Q; Hu Y; Xu A; Wang Z
Channels (Austin); 2022 Dec; 16(1):84-96. PubMed ID: 35389815
[TBL] [Abstract][Full Text] [Related]
40. SWI/SNF Complex Genomic Alterations as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Multiple Cancers.
Wang D; Wang J; Zhou D; Wu Z; Liu W; Chen Y; Chen G; Zhang J
Cancer Immunol Res; 2023 May; 11(5):646-656. PubMed ID: 36848524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
